A comparison of Wharton's jelly and cord blood as a source of mesenchymal stem cells for diabetes cell therapy.
about
Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem CellsCulture of iPSCs Derived Pancreatic β-Like Cells In Vitro Using Decellularized Pancreatic Scaffolds: A Preliminary TrialTherapeutic potential of mesenchymal stem cells for diabetes.Exendin-4 enhances the differentiation of Wharton's jelly mesenchymal stem cells into insulin-producing cells through activation of various β-cell markers.Factors influencing yield and neuronal differentiation of mesenchymal stem cells from umbilical cord blood and matrix.
P2860
A comparison of Wharton's jelly and cord blood as a source of mesenchymal stem cells for diabetes cell therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
A comparison of Wharton's jell ...... lls for diabetes cell therapy.
@en
A comparison of Wharton's jell ...... lls for diabetes cell therapy.
@nl
type
label
A comparison of Wharton's jell ...... lls for diabetes cell therapy.
@en
A comparison of Wharton's jell ...... lls for diabetes cell therapy.
@nl
prefLabel
A comparison of Wharton's jell ...... lls for diabetes cell therapy.
@en
A comparison of Wharton's jell ...... lls for diabetes cell therapy.
@nl
P2093
P2860
P356
P1476
A comparison of Wharton's jell ...... ells for diabetes cell therapy
@en
P2093
Hala O El Mesallamy
Lamiaa N Hammad
Rasha F El-Demerdash
P2860
P304
P356
10.2217/RME.15.49
P577
2015-11-06T00:00:00Z